CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Noninvasive Nuclear SPECT Myocardial Blood Flow Quantitation to Guide Management for Coronary Artery Disease Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

Clinical Case Study2017 Sep;42(9):e400-e402.

JOURNAL:Clin Nucl Med. Article Link

Noninvasive Nuclear SPECT Myocardial Blood Flow Quantitation to Guide Management for Coronary Artery Disease

Chen LC, Jong BH, Lin SC et al. Keywords: myocardial blood flow quantitation; dynamic SPECT; multivessel coronary artery disease; myocardial perfusion

ABSTRACT

Recently, myocardial bloodflow quantitation with dynamic SPECT has been validated to enhance the detection of multivessel coronary artery disease (CAD) and conclude equivocal SPECT myocardial perfusion study. This advance opened an important clinical application to utilize the tool in guiding CAD management for area where myocardial perfusion tracers for PET are unavailable or unaffordable. We present a clinical patient with ongoing recursive angina who underwent multiple nuclear stress tests for a sequence of CAD evaluation in 26 months and demonstrated that SPECT myocardial bloodflow quantitation properly guided CAD management to warrant patient outcome.